三药联合治疗方案加速淋巴丝虫病的消除：从构思到实施。
A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery.
机构信息
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Bridges to Development, Seattle, Washington, USA.
出版信息
Int Health. 2020 Dec 22;13(Suppl 1):S60-S64. doi: 10.1093/inthealth/ihaa046.
Abstract
The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown that a single dose of a triple-drug combination comprised of ivermectin, diethylcarbamazine and albendazole (IDA) is dramatically superior to widely used two-drug combinations for clearing larval filarial parasites from the blood of infected persons. A large multicenter community study showed that IDA was well-tolerated when it was provided as MDA. IDA was rapidly advanced from clinical trial to policy and implementation; it has the potential to accelerate LF elimination in many endemic countries.
摘要
全球消灭淋巴丝虫病规划（LF）正在使用抗丝虫药物进行大规模药物治疗（MDA），以治疗丝虫感染、预防疾病和阻断传播。每年有近 5 亿人接受这些药物治疗。最近的临床试验表明，伊维菌素、乙胺嗪和阿苯达唑（IDA）组成的三药组合一剂即可显著优于广泛使用的二药组合，从受感染者的血液中清除幼虫期丝虫寄生虫。一项大型多中心社区研究表明，当 MDA 提供时，IDA 具有良好的耐受性。IDA 已迅速从临床试验推进到政策和实施阶段；它有可能加速许多流行国家的 LF 消除。
相似文献
1
A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery.三药联合治疗方案加速淋巴丝虫病的消除：从构思到实施。
Int Health. 2020 Dec 22;13(Suppl 1):S60-S64. doi: 10.1093/inthealth/ihaa046.
2
An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.一项开放性标签、随机临床试验，旨在比较伊维菌素加乙胺嗪和阿苯达唑与乙胺嗪加阿苯达唑治疗印度尼西亚班氏丝虫病的耐受性和疗效。
PLoS Negl Trop Dis. 2021 Mar 29;15(3):e0009294. doi: 10.1371/journal.pntd.0009294. eCollection 2021 Mar.
3
Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment.伊维菌素、乙胺嗪和阿苯达唑三联疗法加速肯尼亚淋巴丝虫病消除：方案实施和首次影响评估结果。
PLoS Negl Trop Dis. 2024 Jul 8;18(7):e0011942. doi: 10.1371/journal.pntd.0011942. eCollection 2024 Jul.
4
Safety and effectiveness of triple-drug therapy with ivermectin, diethylcarbamazine, and albendazole in reducing lymphatic filariasis prevalence and clearing circulating filarial antigens in Mombasa, Kenya.伊维菌素、乙胺嗪和阿苯达唑三联药物疗法在肯尼亚蒙巴萨降低淋巴丝虫病流行率及清除循环丝虫抗原方面的安全性和有效性。
Infect Dis Poverty. 2025 Feb 24;14(1):11. doi: 10.1186/s40249-025-01282-z.
5
Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.伊维菌素、乙胺嗪加阿苯达唑群体药物治疗与乙胺嗪加阿苯达唑降低巴布亚新几内亚淋巴丝虫病流行率：一项群组随机试验。
Lancet Infect Dis. 2022 Aug;22(8):1200-1209. doi: 10.1016/S1473-3099(22)00026-3. Epub 2022 May 6.
6
Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis.阿苯达唑单独使用或与抗微丝蚴药物联合用于治疗淋巴丝虫病。
Cochrane Database Syst Rev. 2019 Jan 8;1(1):CD003753. doi: 10.1002/14651858.CD003753.pub4.
7
Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.确定撒哈拉以南非洲地区主要丝虫病的共同流行地区：在大规模药物治疗运动中寻求协同作用并预防严重不良事件。
Parasit Vectors. 2018 Jan 31;11(1):70. doi: 10.1186/s13071-018-2655-5.
8
Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.在巴布亚新几内亚，使用阿苯达唑+乙胺嗪+伊维菌素单剂量三药方案进行大规模药物治疗治疗淋巴丝虫病的安全性和有效性：一项开放性、群组随机试验。
PLoS Negl Trop Dis. 2022 Feb 9;16(2):e0010096. doi: 10.1371/journal.pntd.0010096. eCollection 2022 Feb.
9
Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned.印度加速消除淋巴丝虫病的三联药物疗法介绍：经验教训
Am J Trop Med Hyg. 2022 Mar 15;106(5_Suppl):29-38. doi: 10.4269/ajtmh.21-0964. Print 2022 May 11.
10
Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis.大规模三药联合群体服药耐受性和可接受性研究的经验教训，该研究旨在支持政策变革并加速消除淋巴丝虫病。
Am J Trop Med Hyg. 2022 Mar 15;106(5_Suppl):13-17. doi: 10.4269/ajtmh.21-0840. Print 2022 May 11.
引用本文的文献
1
Validation of the Brugia Test Plus to detect IgG4 antibodies in individuals from Belitung Timur, a Brugia malayi endemic area in Indonesia.在印度尼西亚布鲁氏马来丝虫病流行区东勿里洞岛对Brugia Test Plus检测IgG4抗体的验证。
PLoS Negl Trop Dis. 2025 Aug 20;19(8):e0013449. doi: 10.1371/journal.pntd.0013449. eCollection 2025 Aug.
2
Evaluation of Microfilaremic Individuals after Mass Drug Treatment with Ivermectin, Diethylcarbamazine, and Albendazole for Lymphatic Filariasis in Papua New Guinea.在巴布亚新几内亚，用伊维菌素、乙胺嗪和阿苯达唑进行大规模药物治疗淋巴丝虫病后，对微丝蚴血症患者的评估。
Am J Trop Med Hyg. 2025 Mar 25;112(6):1235-1239. doi: 10.4269/ajtmh.24-0382. Print 2025 Jun 4.
3
Ongoing transmission of lymphatic filariasis in Samoa 4.5 years after one round of triple-drug mass drug administration.萨摩亚在一轮三药药物治疗后 4.5 年内仍有淋巴丝虫病传播。
PLoS Negl Trop Dis. 2024 Jun 27;18(6):e0012236. doi: 10.1371/journal.pntd.0012236. eCollection 2024 Jun.
4
Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?加速实现2030年被忽视热带病目标：定量建模如何支持规划决策？
Clin Infect Dis. 2024 Apr 25;78(Suppl 2):S83-S92. doi: 10.1093/cid/ciae082.
5
Five years of post-validation surveillance of lymphatic filariasis in Thailand.泰国淋巴丝虫病五年验证后监测。
Infect Dis Poverty. 2023 Dec 6;12(1):113. doi: 10.1186/s40249-023-01158-0.
6
Lymphatic filariases and soil-transmitted helminthiases in Sri Lanka: the challenge of eliminating residual pockets of transmission.斯里兰卡的淋巴丝虫病和土壤传播性蠕虫病：消除剩余传播点的挑战。
Philos Trans R Soc Lond B Biol Sci. 2023 Oct 9;378(1887):20220280. doi: 10.1098/rstb.2022.0280. Epub 2023 Aug 21.
7
Reconstructive Surgery for the Neglected Tropical Diseases: Global Gaps and Future Directions.被忽视热带病的重建外科手术：全球差距与未来方向
Plast Reconstr Surg Glob Open. 2023 May 17;11(5):e4987. doi: 10.1097/GOX.0000000000004987. eCollection 2023 May.
8
Lymphatic filariasis endgame strategies: Using GEOFIL to model mass drug administration and targeted surveillance and treatment strategies in American Samoa.淋巴丝虫病终期策略：使用 GEOFIL 模型模拟在美属萨摩亚的大规模药物治疗和有针对性的监测与治疗策略。
PLoS Negl Trop Dis. 2023 May 18;17(5):e0011347. doi: 10.1371/journal.pntd.0011347. eCollection 2023 May.
9
Policy stakeholder perspectives on barriers and facilitators to launching a community-wide mass drug administration program for soil-transmitted helminths.政策利益相关者对开展社区范围大规模驱虫药物治疗计划的障碍和促进因素的看法。
Glob Health Res Policy. 2022 Dec 2;7(1):47. doi: 10.1186/s41256-022-00281-z.
10
Development of Pyrazolopyrimidine Anti- Agents for the Treatment of Filariasis.用于治疗丝虫病的吡唑并嘧啶类抗寄生虫药物的研发。
ACS Med Chem Lett. 2021 Aug 20;12(9):1421-1426. doi: 10.1021/acsmedchemlett.1c00216. eCollection 2021 Sep 9.
本文引用的文献
1
Single-Dose Triple-Drug Therapy for - 5-Year Follow-up.单剂量三联药物疗法的5年随访
N Engl J Med. 2020 May 14;382(20):1956-1957. doi: 10.1056/NEJMc1914262.
2
Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d'Ivoire: An Open-label Randomized Controlled Trial.伊维菌素、乙胺嗪和阿苯达唑单次剂量治疗科特迪瓦淋巴丝虫病的疗效和安全性：一项开放标签随机对照试验。
Clin Infect Dis. 2020 Oct 23;71(7):e68-e75. doi: 10.1093/cid/ciz1050.
3
Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach.剂量杆推荐用于淋巴丝虫病消除：一种身高-体重分位数回归建模方法。
PLoS Negl Trop Dis. 2019 Jul 17;13(7):e0007541. doi: 10.1371/journal.pntd.0007541. eCollection 2019 Jul.
4
The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.双、三药社区全民药物治疗丝虫病的安全性：一项多中心、开放性、整群随机研究。
PLoS Med. 2019 Jun 24;16(6):e1002839. doi: 10.1371/journal.pmed.1002839. eCollection 2019 Jun.
5
A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.一种治疗丝虫病的三药疗法试验。
N Engl J Med. 2018 Nov 8;379(19):1801-1810. doi: 10.1056/NEJMoa1706854.
6
Predicting lymphatic filariasis transmission and elimination dynamics using a multi-model ensemble framework.利用多模型集成框架预测淋巴丝虫病传播和消除动态。
Epidemics. 2017 Mar;18:16-28. doi: 10.1016/j.epidem.2017.02.006.
7
GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction.GRADE证据到决策（EtD）框架：一种做出明智医疗选择的系统且透明的方法。1：引言。
BMJ. 2016 Jun 28;353:i2016. doi: 10.1136/bmj.i2016.
8
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.二乙碳酰氨嗪、阿苯达唑和伊维菌素联合治疗班氏丝虫病的疗效、安全性和药代动力学。
Clin Infect Dis. 2016 Feb 1;62(3):334-341. doi: 10.1093/cid/civ882. Epub 2015 Oct 20.
9
Antibiotics for the treatment of onchocerciasis and other filarial infections.用于治疗盘尾丝虫病和其他丝虫感染的抗生素。
Curr Opin Investig Drugs. 2002 Apr;3(4):533-7.
Zotero 插件